Open AccessRNA methylation in hematological malignancies and its interactions with other epigenetic modifications
Author(s) -
Lan Yao,
Hua Yin,
Min Hong,
Yajun Wang,
Tingting Yu,
Yuanwen Teng,
Tingting Li,
Qirui Wu
Publication year - 2021
Publication title -
leukemia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.539
H-Index - 192
eISSN - 1476-5551
pISSN - 0887-6924
DOI - 10.1038/s41375-021-01225-1
Subject(s) - epigenetics , biology , dna methylation , carcinogenesis , histone , haematopoiesis , cancer research , methylation , rna , cancer , stem cell , genetics , dna , gene , gene expression
Hematological malignancies are a class of malignant neoplasms attributed to abnormal differentiation of hematopoietic stem cells (HSCs). The systemic involvement, poor prognosis, chemotherapy resistance, and recurrence common in hematological malignancies urge researchers to look for novel treatment targets and mechanisms. In recent years, epigenetic abnormalities have been shown to play a vital role in tumorigenesis and progression in hematological malignancies. In addition to DNA methylation and histone modifications, which are most studied, RNA methylation has become increasingly significant. In this review, we elaborate recent advances in the understanding of RNA modification in the pathogenesis, diagnosis and molecular targeted therapies of hematological malignancies and discuss its intricate interactions with other epigenetic modifications, including DNA methylation, histone modifications and noncoding RNAs.